Live Analyst Rating Changes 25366 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Yee
UBS

Michael Yee

Wall Street Analyst
★★★☆☆
#1558
on 13Foresight · ranked by our own returns
63%
Success Rate
+11.1%
Average Return
66 of 105 calls profitable · +46.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of Michael Yee's ratings turned a profit when each position was held for 1 year — averaging +11.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

97 Buy 27 Hold 0 Sell
Michael's Stock Coverage 77 ratings · 2026-08-18
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
KOD
Kodiak Sciences
Aug 14, 2026 BUY Strong Buy
+27.2% avg upside
11 analysts
$80.00
95.18% Upside
+0.0% ·
TRAX
First Tracks Biotherapeutics Inc
Aug 13, 2026 BUY Strong Buy
+35.2% avg upside
8 analysts
$65.00
49.03% Upside
+0.0% ·
BMY
Bristol-Myers Squibb
Aug 13, 2026 BUY Buy
-5.5% avg upside
42 analysts
$80.00
23.80% Upside
-1.1% ·
DNLI
Denali Therapeutics
Aug 07, 2026 BUY Strong Buy
+57.8% avg upside
24 analysts
$34.00
39.59% Upside
-1.7% ·
AMGN
Amgen
Aug 05, 2026 BUY Buy
-24.2% avg upside
57 analysts
$440.00
4.93% Upside
+1.8% ·
RVMD
Revolution Medicines
Aug 05, 2026 BUY Strong Buy
-20.1% avg upside
32 analysts
$220.00
3.71% Upside
+8.7% ·
LLY
Eli Lilly & Co
Aug 05, 2026 BUY Strong Buy
-12.2% avg upside
48 analysts
$1425.00
20.34% Upside
+1.0% ·
VRTX
Vertex Pharmaceuticals
Aug 04, 2026 BUY Strong Buy
-13.5% avg upside
62 analysts
$585.00
13.41% Upside
+5.7% ·
BIIB
Biogen
Jul 30, 2026 BUY Strong Buy
+20.8% avg upside
52 analysts
$240.00
14.71% Upside
+0.9% ·
GILD
Gilead Sciences
Jul 28, 2026 BUY Strong Buy
-14.3% avg upside
66 analysts
$175.00
25.93% Upside
+3.0% ·
MBX
MBX Biosciences, Inc.
Jul 24, 2026 BUY Strong Buy
+15.8% avg upside
14 analysts
$90.00
31.91% Upside
+10.6% ·
ABBV
AbbVie
Jul 13, 2026 HOLD Strong Buy
-3.9% avg upside
46 analysts
$260.00
3.92% Upside
+1.3% ·
ORKA
Oruka Therapeutics
Jul 02, 2026 BUY Strong Buy
+12.4% avg upside
16 analysts
$130.00
15.33% Upside
+30.3% ·
ANAB
AnaptysBio
Jun 30, 2026 BUY Strong Buy
+22.3% avg upside
26 analysts
$76.00
27.37% Upside
-13.4% ·
PFE
Pfizer
Jun 23, 2026 HOLD Buy
+24.9% avg upside
45 analysts
$27.00
0.57% Upside
+10.6% ·
APGE
Apogee Therapeutics
Jun 23, 2026 HOLD Buy
-5.4% avg upside
19 analysts
$135.11
0.43% Upside
+1.3% ·
JBIO
Jade Biosciences
Jun 15, 2026 BUY Strong Buy
+141.2% avg upside
16 analysts
$45.00
91.95% Upside
+53.5% ·
IVA
Inventiva
Jun 12, 2026 BUY Strong Buy
+240.4% avg upside
17 analysts
$12.00
155.24% Upside
+19.5% ·
IDYA
IDEAYA Biosciences
Jun 09, 2026 BUY Strong Buy
+32.7% avg upside
29 analysts
$50.00
36.82% Upside
+30.2% ·
MRK
Merck & Company
Jun 02, 2026 BUY Strong Buy
-4.8% avg upside
43 analysts
$145.00
6.72% Upside
+18.3% ·
OLMA
Olema Pharmaceuticals
Jun 02, 2026 BUY Strong Buy
+256.9% avg upside
16 analysts
$45.00
317.79% Upside
-0.6% ·
MRNA
Moderna
Jun 02, 2026 HOLD Hold
+10.5% avg upside
38 analysts
$45.00
30.21% Downside
+38.7% ·
COGT
Cogent Biosciences
May 31, 2026 BUY Strong Buy
-0.9% avg upside
26 analysts
$60.00
58.52% Upside
+9.0% ·
ALXO
ALX Oncology Holdings
May 12, 2026 BUY Strong Buy
+817.3% avg upside
11 analysts
$6.00
204.66% Upside
-3.5% ·
SDGR
Schrodinger
Mar 17, 2026 HOLD Strong Buy
+58.3% avg upside
15 analysts
$13.00
25.27% Downside
+43.1% ·
ALGS
Aligos Therapeutics
Mar 05, 2026 BUY Strong Buy
+600.7% avg upside
11 analysts
$20.00
204.13% Upside
+3.5% ·
NUVB
Nuvation Bio
Mar 03, 2026 HOLD Strong Buy
+108.7% avg upside
15 analysts
$7.00
8.00% Upside
+42.7% ·
SABS
SAB Biotherapeutics
Feb 25, 2026 BUY Strong Buy
+182.6% avg upside
14 analysts
$7.00
85.68% Upside
-5.9% ·
DMRA
Damora Therapeutics
Feb 17, 2026 BUY Strong Buy
-7.1% avg upside
20 analysts
$45.00
44.84% Upside
+3.8% ·
ZLAB
Zai Lab
Jan 07, 2026 BUY Strong Buy
+129.7% avg upside
13 analysts
$35.00
36.60% Upside
+36.1% ·
SRRK
Scholar Rock Holding
Jan 07, 2026 BUY Strong Buy
+10.6% avg upside
23 analysts
$60.00
15.32% Upside
+18.7% ·
VRDN
Viridian Therapeutics
Jan 07, 2026 BUY Strong Buy
+52.6% avg upside
32 analysts
$50.00
116.64% Upside
-27.8% ·
ALLO
Allogene Therapeutics
Jan 06, 2026 BUY Strong Buy
+635.8% avg upside
28 analysts
$8.00
284.69% Upside
+45.7% ·
IMCR
Immunocore Holdings
Jan 06, 2026 BUY Strong Buy
+84.5% avg upside
22 analysts
$55.00
57.00% Upside
+4.1% ·
BEAM
Beam Therapeutics
Jan 06, 2026 HOLD Strong Buy
+92.2% avg upside
25 analysts
$28.00
3.36% Upside
-5.6% ·
IMRX
Immuneering
Jun 25, 2025 HOLD Strong Buy
+249.6% avg upside
12 analysts
$3.50
33.01% Downside
+50.0% ·
PRTA
Prothena
May 27, 2025 HOLD Buy
+181.4% avg upside
14 analysts
$6.00
32.45% Downside
+119.0% ·
IOVA
Iovance Biotherapeutics
Mar 13, 2025 BUY Strong Buy
+87.5% avg upside
24 analysts
$18.00
153.47% Upside
+12.5% ·
FATE
Fate Therapeutics
Mar 06, 2025 BUY Buy
+366.2% avg upside
31 analysts
$8.00
205.38% Upside
+27.9% ·
LIANY
LianBio Sponsored ADR
Dec 22, 2023 HOLD Hold
+27542.5% avg upside
4 analysts
$4.00
8970.32% Upside
· ·
AMRN
Amarin
Oct 25, 2023 HOLD Hold
-39.8% avg upside
18 analysts
$1.00
92.83% Downside
-18.3% ·
EXEL
Exelixis
Mar 22, 2023 BUY Buy
-17.0% avg upside
34 analysts
$26.00
50.24% Downside
+29.9% ·
IVVD
Invivyd
Dec 22, 2021 HOLD Buy
+998.6% avg upside
8 analysts
$10.00
1250.47% Upside
-81.5% ·
KYNB
Kyntra Bio
Aug 10, 2021 HOLD Buy
+356.6% avg upside
15 analysts
$15.00
120.31% Upside
· ·
ASMB
Assembly Biosciences
Dec 21, 2020 HOLD Strong Buy
+10.9% avg upside
10 analysts
$7.00
76.68% Downside
-63.7% ·
ODTC
Odonate
Dec 21, 2018 BUY Hold
-99.9% avg upside
3 analysts
$31.00
99.91% Downside
· ·
TLPH
Talphera
Jul 08, 2018 HOLD Buy
+284.6% avg upside
15 analysts
$3.50
191.60% Upside
· ·
DCOY
Decoy Therapeutics
Jul 08, 2018 HOLD Strong Buy
+671.9% avg upside
7 analysts
$1.00
71.55% Downside
· ·
VNDA
Vanda
Jul 08, 2018 BUY Strong Buy
+281.2% avg upside
13 analysts
$22.00
318.30% Upside
-32.1% ·
CLLS
Cellectis SA
Oct 27, 2017 BUY Strong Buy
+549.4% avg upside
16 analysts
$47.00
1411.34% Upside
-25.9% ·
AFMDQ
Affimed
Oct 02, 2017 HOLD Buy
+14226263.6% avg upside
16 analysts
$2.50
2499900.01% Upside
· ·
BMRN
BioMarin Pharmaceutical
Sep 25, 2017 BUY Strong Buy
+43.1% avg upside
52 analysts
$116.00
74.05% Upside
+2.0% ·
ACAD
ACADIA Pharmaceuticals
Sep 04, 2017 BUY Strong Buy
+27.2% avg upside
43 analysts
$47.00
62.05% Upside
-59.6% ·
RIGL
Rigel
Sep 04, 2017 BUY Buy
-36.5% avg upside
17 analysts
$5.00
88.13% Downside
+37.2% ·
AGEN
Agenus
Sep 04, 2017 BUY Strong Buy
+23.1% avg upside
18 analysts
$7.00
2.19% Downside
· ·
UTHR
United Therapeutics
Feb 23, 2017 HOLD Strong Buy
-15.1% avg upside
26 analysts
$110.00
78.32% Downside
-19.9% ·
REGN
Regeneron
Jan 03, 2017 BUY Strong Buy
-2.4% avg upside
58 analysts
$626.00
22.35% Downside
+3.7% ·
PBYI
Puma Biotechnology
Dec 30, 2016 HOLD Hold
+378.8% avg upside
11 analysts
$57.00
546.16% Upside
+222.0% ·
MTVA
MetaVia
Dec 20, 2016 BUY Strong Buy
+1915.3% avg upside
13 analysts
$25.00
1589.24% Upside
· ·
INCY
Incyte
Nov 14, 2016 BUY Buy
-11.8% avg upside
47 analysts
$113.00
8.45% Downside
+0.2% ·
BSX
Boston Scientific
Oct 02, 2016 BUY Strong Buy
+31.4% avg upside
38 analysts
$28.00
45.61% Downside
+25.4% ·
SYK
Stryker
Oct 02, 2016 BUY Strong Buy
+10.7% avg upside
37 analysts
$129.00
61.06% Downside
+24.8% ·
MDT
Medtronic
Oct 02, 2016 BUY Buy
+6.1% avg upside
38 analysts
$95.00
4.85% Upside
-7.6% ·
JNJ
Johnson & Johnson
Oct 02, 2016 BUY Strong Buy
-9.3% avg upside
39 analysts
$133.00
49.31% Downside
+13.4% ·
ABT
Abbott Laboratories
Oct 02, 2016 BUY Strong Buy
+4.9% avg upside
36 analysts
$48.00
56.45% Downside
+29.3% ·
RRX
Regal Rexnord
Jul 28, 2016 BUY Strong Buy
+11.6% avg upside
20 analysts
$115.00
34.11% Downside
+40.4% ·
INFIQ
Infinity Pharmaceuticals
Jun 15, 2016 HOLD Buy
+647142757.2% avg upside
8 analysts
$2.00
199999900.07% Upside
· ·
TEVA
Teva Pharmaceutical
Apr 20, 2016 BUY Buy
-17.3% avg upside
39 analysts
$75.00
105.76% Upside
-43.9% ·
SRPT
Sarepta Therapeutics
Feb 05, 2016 HOLD Buy
+228.7% avg upside
49 analysts
$15.00
17.45% Downside
+140.0% ·
ELV
Elevance Health
Jan 25, 2016 BUY Strong Buy
+15.0% avg upside
33 analysts
$193.00
50.53% Downside
+13.0% ·
UNH
UnitedHealth
Jan 25, 2016 BUY Strong Buy
+15.0% avg upside
36 analysts
$157.00
60.25% Downside
+44.7% ·
LRMR
Larimar Therapeutics
Jan 04, 2016 HOLD Strong Buy
+311.4% avg upside
22 analysts
$7.00
61.99% Upside
· ·
ABUS
Arbutus Biopharma
Nov 06, 2015 BUY Strong Buy
+87.3% avg upside
15 analysts
$20.00
324.57% Upside
-50.2% ·
ARWR
Arrowhead Pharmaceuticals
Aug 05, 2015 HOLD Strong Buy
-15.2% avg upside
27 analysts
$9.00
89.83% Downside
-11.5% ·
MYGN
Myriad Genetics
Jun 30, 2014 HOLD Hold
+487.4% avg upside
24 analysts
$40.00
1211.43% Upside
-12.7% ·
ORCL
Oracle
Jun 29, 2012 BUY Strong Buy
+49.5% avg upside
71 analysts
+4.4% ·
MYRX
Myrexis
Mar 20, 2012 BUY Strong Buy
+3499899.9% avg upside
2 analysts
$28.00
3499899.94% Upside
· ·
🔒 72 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Michael Yee — Frequently Asked Questions
How accurate are Michael Yee's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Michael's ratings were profitable over a one-year hold, with an average return of +11.1% per rating, or +46.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Michael ranked on 13Foresight?
Michael Yee is currently ranked #1558 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on KOD, TRAX, BMY, DNLI, AMGN, RVMD, LLY, VRTX, BIIB, GILD, MBX, ABBV and 65 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.